Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase II study of hu14.18-IL2 [EMD 273063] in children with recurrent or refractory neuroblastoma

Next Previous
X
Search
Trial Profile

A phase II study of hu14.18-IL2 [EMD 273063] in children with recurrent or refractory neuroblastoma

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 03 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lorukafusp alfa (Primary)
  • Indications Neuroblastoma
  • Focus Therapeutic Use

    • Most Recent Events

    • 02 Feb 2011 This study data provided drug development checkpoints to proceed to phase III in certain pediatric neuroblastoma subjects and Apeiron plans to continue clinical development in 2011, according to an Apeiron Biologics media release.
    • 26 Mar 2008 Status changed from in progress to completed according to clinicaltrials.gov.
    • 01 Oct 2005 New trial record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top